Insulin glargine 300 units/ml: A new basal insulin product for diabetes mellitus

American Journal of Health-System Pharmacy

Volumn 73, Issue 6, 2016, Pages 359-366

  Clements, Jennifer N ^a   Bello, Larkin ^a  

^a PRESBYTERIAN COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOSYLATED HEMOGLOBIN; INSULIN GLARGINE; ISOPHANE INSULIN; ANTIDIABETIC AGENT; DRUG DOSAGE FORM;

ADULT; CONTROLLED STUDY; DIABETES MELLITUS; DRUG COST; DRUG EFFICACY; DRUG SAFETY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN SENSITIVITY; MAJOR CLINICAL STUDY; MALE; NOCTURNAL HYPOGLYCEMIA; NON INSULIN DEPENDENT DIABETES MELLITUS; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; SINGLE DRUG DOSE; STEADY STATE; TREATMENT DURATION; BLOOD; CHEMISTRY; DRUG DOSAGE FORM; PHASE 3 CLINICAL TRIAL (TOPIC); PROCEDURES; RANDOMIZED CONTROLLED TRIAL (TOPIC);

CLINICAL TRIALS, PHASE III AS TOPIC; DIABETES MELLITUS; DOSAGE FORMS; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN GLARGINE; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84962650459     PISSN: 10792082     EISSN: 15352900     Source Type: Journal    
DOI: 10.2146/ajhp150174     Document Type: Review

References (26)

1. Centers for Disease Control and Prevention. National diabetes fact sheet: national estimates and general information on diabetes and prediabetes in the United States, 2015. Atlanta, GA: Centers for Disease Control and Prevention; 2014.
2. Centers for Disease Control and Prevention. Diabetes report card, 2012. www.cdc.gov/diabetes/pubs/pdf/DiabetesReportCard.pdf (accessed 2014 Dec. 16).
3. Rizza RA, Gerich JE, Haymond MW et al. Control of blood sugar in insulindependent diabetes: comparison of an artificial endocrine pancreas, continuous subcutaneous insulin infusion and intensified conventional insulin therapy. N Engl J Med. 1980;303:1313-8.
4. Inzucchi SE, Bergenstal RM, Buse JB et al. Management of hyperglycemia in type 2 diabetes, 2015: a patientcentered approach: update to a position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2015;38:140-9.
5. Garber AJ, Abrahamson MJ, Barzilay JI et al. AACE/ACE comprehensive diabetes management algorithm. Endocr Pract. 2015;21:438-47.
6. Berkrot B. Sanofi's diabetes drug Toujeo gets U. S. approval, label disappoints. www.reuters.com/article/2015/02/26/us-sanofi-sadiabetes-toujeo-idUSKBN0LU 13I20150226 (accessed 2015 Mar. 9).
7. Shiramoto M, Eto T, Irie S et al. Single-dose new insulin glargine 300 U/ml provides prolonged, stable glycaemic control in Japanese and European people with type 1 diabetes. Diabetes Obes Metab. 2015;17:254-60.
8. Becker RH, Dahmen R, Bergmann K et al. New insulin glargine 300 units/mL provides a more even activity profile and prolonged glycemic control at steady state compared with insulin glargine 100 units/mL. Diabetes Care. 2015;38:637-43.
9. Steinstrasesser A, Schmidt R, Bergmann K et al. Investigational new insulin glargine 300 U/ml has the same metabolism as insulin glargine 100 U/ml. Diabetes Obes Metab. 2014;16:873-6.
10. Becker RH, Nowotny I, Teichert L et al. Low within- and between-day variability in exposure to new insulin glargine 300 U/ml. Diabetes Obes Metab. 2015;17:261-7.
11. Jinnouchi H, Koyama M, Amano A et al. Continuous glucose monitoring during basal-bolus therapy using insulin glargine 300 U mL and glargine 100 U mL in Japanese people with type 1 diabetes mellitus: a crossover pilot study. Diabetes Ther. 2015;6:143-52.
12. Riddle MC, Bolli GB, Zieman M et al. New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 2 diabetes using basal and mealtime insulin: glucose control and hypoglycemia in a 6-month randomized, controlled trial (EDITION 1). Diabetes Care. 2014;37:2755-62.
13. Yki-Jarvinen H, Bergenstal R, Ziemen M et al. New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 2 diabetes using oral agents and basal insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 2). Diabetes Care. 2014;37:3235-43.
14. Bolli GB, Riddle MC, Bergenstal RM et al. New insulin glargine 300 U/ml compared with glargine 100 U/ml in insulin-naïve people with type 2 diabetes on oral glucose-lowering drugs: a randomized controlled trial (EDITION 3). Diabetes Obes Metab. 2015;17:386-94.
15. Home PD, Bergenstal RM, Bolli GB et al. New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 1 diabetes: a randomized, Phase 3A, open-label clinical trial (EDITION 4). Diabetes Care. 2015;38:2217-25.
16. Riddle MC, Yki-Jarvinen H, Bolli GB et al. One-year sustained glycaemic control and less hypoglycaemia with new insulin glargine 300 U/ml compared with 100 U/ml in people with type 2 diabetes using basal plus meal-time insulin: the EDITION 1 12-month randomized trial, including 6-month extension. Diabetes Obes Metab. 2015;17:835-42.
17. Yki-Jarvinen H, Vergenstal RM, Bolli GB et al. Glycaemic control and hypoglycaemia with new insulin glargine 300 U/mL versus glargine 100 U/mL in people with type 2 diabetes using basal insulin and oral antihyperglycaemic drugs (EDITION 2 randomized 12-month trial including 6-month extension). Diabetes Obes Metab. 2015;17:1142-9.
18. Ritzel R, Roussel R, Bolli GB et al. Patient-level meta-analysis of the EDITION 1, 2, and 3 studies: glycaemic control and hypoglycaemia with new insulin glargine 300 U/ml versus glargine 100 U/ml in people with type 2 diabetes. Diabetes Obes Metab. 2015;17:859-67.
19. Matsuhisa M, Koyama M, Cheng X et al. New insulin glargine 300 U/mL: glycemic control and hypoglycemia in Japanese people with T1DM (EDITION JP 1) (abstract 88-LB). Diabetes. 2014;63(suppl 1):LB22.
20. Terauchi Y, Koyama M, Cheng X et al., on behalf of the EDITION JP 2 Study Group. Glycemic control and hypoglycemia in Japanese people with T2DM receiving new insulin glargine 300 U/mL in combination with OADs (EDITION JP 2) (abstract 94-LB). Diabetes. 2014;63(suppl 1):LB24.
21. Toujeo (insulin glargine 300 units/mL) prescribing information. Bridgewater, NJ: Sanofi-Aventis U. S. LLC; 2015 Feb.
22. Heller S, Buse J, Fisher M et al. Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-totarget non-inferiority trial. Lancet. 2012;379:1489-97.
23. Garber AJ, King AB, Del Prato S et al. Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-totarget non-inferiority trial. Lancet. 2012;379:1498-507.
24. Gerstein HC, Bosch J, Dagenais GR et al. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med. 2012;367:319-28.
25. Toujeo. In: Red Book Online [online database]. Greenwood Village, CO: Truven Health Analytics (accessed 2015 yJul. 17).
26. Lantus. In Red Book Online [online database]. Greenwood Village, CO: Truven Health Analytics; (accessed 2015 Jul. 17).